The new deal – financial terms of which were not disclosed – will combine the ClinPhone randomization and trial supply management tech developed by Parexel’s eClinical subsidiary – Perceptive Informatics - with Fuijitsu System’s DDworks 21 GCP risk management solution.
Transferring data captured by ClinPhone to the Fujitsu tech directly will improve efficiency according to Perceptive’s Graham Bunn, who said: “Clinical trial management is often hindered by complex, time-consuming manual processes for collecting, aggregating and rationalizing data.”
"Integrating our industry-leading technologies will replace fragmented methods for capturing and leveraging data. By streamlining these processes, clients can conduct clinical trials more efficiently."
The agreement fits with other eClinical deals Parexel has made in the region. In May the firm set up its sixth operations in China – in Shenyang – in a move it said would enables Parexel “to bring Perceptive eClinical technology solutions to the Asia Pacific market.”
Parexel has also recently set up support offices in both China and Japan – in Shanghai, Kobe and Tokyo, respectively – specifically to support both international and local developers using services offered by Perceptive Informatics.
And across the wider region, the US contract research organisation (CRO) also has trial technology-focused deals with the Korean Drug Development Fund (KDDF) in Seoul and the National Taiwan University Hospital (NTUH) in Taiwan.
Fuijitsu Systems is a computer systems engineering company whose clinical trial offering – DDworks 21 – is described as a good clinical practices (GCP) risk management solution that helps developers with “quality and regulatory compliance in Japan.”
These capabilities are similar to those offered by recent Parexel acquisition Liquent, which provides regulatory information management software and has offices in the UK, Germany and India.